Pure Bioscience, Inc. (PURE) — 8-K Filings

8-K Filings (8)

• 8-K Filing — May 5, 2026
• Pure Bioscience Reports Director Changes and Compensation — Nov 19, 2025 Risk: medium
  Pure Bioscience, Inc. filed an 8-K on November 19, 2025, reporting on the departure of directors, election of new directors, and compensatory arrangements. The
• Pure Bioscience Reports Shareholder Vote — Jan 28, 2025 Risk: low
  Pure Bioscience, Inc. filed an 8-K on January 28, 2025, reporting on a matter submitted to a vote of its security holders on January 22, 2025. The filing does n
• Pure Bioscience Reports Definitive Agreement and Equity Sales — Sep 20, 2024 Risk: medium
  Pure Bioscience, Inc. entered into a material definitive agreement on September 16, 2024, which involves a direct financial obligation or an off-balance sheet a
• Pure Bioscience Changes Fiscal Year End — Aug 9, 2024 Risk: low
  Pure Bioscience, Inc. filed an 8-K on August 9, 2024, reporting a change in its fiscal year end to July 31, with the most recent fiscal year ending on July 31,
• Pure Bioscience Appoints New Directors, Krall Resigns — May 7, 2024 Risk: low
  Pure Bioscience, Inc. announced on May 1, 2024, a change in its board of directors. Specifically, Michael L. Krall resigned from his position as a director, and
• Pure Bioscience Enters Material Agreement, Reports Equity Sales — Mar 27, 2024 Risk: medium
  Pure Bioscience, Inc. entered into a material definitive agreement on March 22, 2024, which involves a direct financial obligation. The company also reported un
• PURE BIOSCIENCE Files 8-K on Shareholder Vote Matters — Feb 26, 2024 Risk: low
  PURE BIOSCIENCE, INC. filed an 8-K on February 26, 2024, reporting on matters submitted to a vote of security holders on February 21, 2024. The filing indicates

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX